1473. Current Status of Antimicrobial Stewardship Programs in Pediatrics in Japan
Session: Poster Abstract Session: Antimicrobial Stewardship: Pediatric and OPAT
Saturday, October 10, 2015
Room: Poster Hall
Posters
  • mihoko isogai.pdf (198.8 kB)
  • Background: According to national surveillance in Japan, 16,556 people died from nosocomial infections caused by antimicrobial resistant organisms in 2013. Although appropriate antimicrobial stewardship program (ASP) is essential, little is known regarding the status of ASP in pediatrics in Japan. The aim of our study is to describe ASP, antibiotic use density (AUD) and susceptibility of Pseudomonas aeruginosa in pediatric facilities in Japan.

    Methods: Retrospective survey was conducted among 31 pediatric medical facilities registered for Japanese Association of Children's Hospitals and Related Institutions from 2012 to 2014. Survey items included hospital type, hospital demographics, types of pediatric subspecialty services, content of ASP, AUD of carbapenems by day of treatment (DOT)/1000 patient-days and carbapenems’ susceptibility of P. aeruginosa.

    Results: There were 15 free-standing children’s hospitals, 12 tertiary hospitals with pediatrics and 4 chronic care hospitals for pediatrics. There were a median of 142 pediatric beds and 45,847 pediatric admissions per year. Of these, 68% had requirements for reporting carbapenem use, 21% required prior authorization for prescription of carbapenems and 11% had no restrictions. AUDs of free-standing children’s hospitals were higher than other types of hospitals. AUDs of carbapenems among free-standing children’s hospitals varied from 0.59 to 42.64 (DOT/1000 patient-days). Content of ASP and existence of specific pediatric subspecialty services were not associated with higher AUD. Coefficient of correlation value between AUD of carbapenems and carbapenems’ susceptibility of P. aeruginosa was not significant.

    Conclusion: This first report comparing the status of ASP among pediatric facilities in Japan revealed a wide variety of carbapenems AUDs in free-standing children’s hospitals and indicate that there is room for improvement in hospitals with prominently high AUDs.

    Mihoko Isogai, MD1, Yoshihiko Morikawa, MD2, Shigeko Miyokawa, RN3, Yoshie Sugawara, RN4, Isao Miyairi, MD5, Yuho Horikoshi, MD1 and Japanese Association of Children's Hospitals and Related Institutions, (1)Infectious Diseases, Tokyo Metropolitan Children's Medical Center, Tokyo, Japan, (2)Clinical Research Support Center, Tokyo Metropolitan Children's Medical Center, Fuchu-shi, Japan, (3)Nursing, Tokyo Metropolitan Children’s Medical Center, Fuchu, Japan, (4)Nursing, National Center for Child Health and Development, Tokyo, Japan, (5)Infectious Disease, National Center for Child Health and Development, Tokyo, Japan

    Disclosures:

    M. Isogai, None

    Y. Morikawa, None

    S. Miyokawa, None

    Y. Sugawara, None

    I. Miyairi, Dainippon sumitomo: speaker at a sponsored program , Speaker honorarium
    Kyorin pharmaceuticals: speaker at sponsored lecture , Speaker honorarium
    Astellas: speaker at sponsored lecture , Speaker honorarium
    Teijin pharm: speaker at sponsored lecture , Speaker honorarium
    Daiichi sankyo: speaker at sponsored lecture , Speaker honorarium
    Takeda pharm: speaker at sponsored lecture , Speaker honorarium
    Tanabe mitsubishi: speaker at sponsored lecture , Speaker honorarium
    Janssen: Grant Investigator , Research grant

    Y. Horikoshi, Sumitomo Pharm: Speaker at sponsored symposium , Speaker honorarium
    Asahi Kasei: Grant Investigator , Grant recipient
    Taisho Toyama Pharm: Speaker at sponsored symposium , Speaker honorarium
    Meiji Seika pharma: Speaker at sponsored symposium , Speaker honorarium
    Pfizer: Speaker at sponsored symposium , Speaker honorarium

    Findings in the abstracts are embargoed until 12:01 a.m. PDT, Wednesday Oct. 7th with the exception of research findings presented at the IDWeek press conferences.